Integra LifeSciences Holdings Corporation (IART) Stock Rating Lowered by Zacks Investment Research

Integra LifeSciences Holdings Corporation (NASDAQ:IART) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Monday.

According to Zacks, “Over the last six months, Integra Lifesciences has been trading above the broader industry. Moreover, the strong year over year increase in revenue on the back of solid performance of its Orthopedics and Tissue Technologies’ segment buoys optimism. We believe the company’s recent product diversification bolstered investors’ confidence, thereby boosting the stock price further. On the flip side, the company exited the second quarter of 2017 on somewhat disappointing note with earnings in line with the estimates and revenues missing the mark. We are concerned about the currency headwind that is expected to affect Integra’s financial performance in the rest of 2017. Also, contraction in adjusted operating margin and adjusted gross margin adds to the woes.”

IART has been the subject of several other reports. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price objective on shares of Integra LifeSciences Holdings Corporation in a report on Monday, July 10th. Raymond James Financial, Inc. raised their price objective on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a report on Wednesday, July 26th. BidaskClub lowered shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Finally, Jefferies Group LLC restated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a report on Sunday, September 10th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $54.27.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ IART) opened at 49.35 on Monday. The company has a 50-day moving average price of $50.65 and a 200-day moving average price of $49.35. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42. The company has a market capitalization of $3.85 billion, a price-to-earnings ratio of 60.18 and a beta of 0.71.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The business had revenue of $282.16 million during the quarter, compared to analyst estimates of $283.58 million. During the same period last year, the business posted $0.40 earnings per share. Integra LifeSciences Holdings Corporation’s quarterly revenue was up 13.2% compared to the same quarter last year. On average, equities analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.91 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://stocknewstimes.com/2017/10/11/integra-lifesciences-holdings-corporation-iart-stock-rating-lowered-by-zacks-investment-research.html.

In other Integra LifeSciences Holdings Corporation news, Director Barbara B. Hill bought 5,050 shares of the stock in a transaction dated Tuesday, August 1st. The stock was purchased at an average cost of $49.33 per share, for a total transaction of $249,116.50. Following the completion of the acquisition, the director now owns 44,772 shares of the company’s stock, valued at $2,208,602.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Donald E. Morel, Jr. bought 2,500 shares of the stock in a transaction dated Thursday, August 3rd. The shares were acquired at an average price of $49.29 per share, with a total value of $123,225.00. Following the completion of the acquisition, the director now directly owns 29,612 shares of the company’s stock, valued at approximately $1,459,575.48. The disclosure for this purchase can be found here. Insiders have bought 17,550 shares of company stock valued at $864,842 over the last quarter. Company insiders own 21.50% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Acrospire Investment Management LLC increased its position in shares of Integra LifeSciences Holdings Corporation by 280.0% during the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after acquiring an additional 1,400 shares in the last quarter. Riverhead Capital Management LLC increased its position in shares of Integra LifeSciences Holdings Corporation by 49.9% during the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after acquiring an additional 799 shares in the last quarter. LS Investment Advisors LLC increased its position in shares of Integra LifeSciences Holdings Corporation by 4.6% during the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after acquiring an additional 111 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Integra LifeSciences Holdings Corporation by 223.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after acquiring an additional 1,751 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA bought a new stake in shares of Integra LifeSciences Holdings Corporation during the second quarter valued at approximately $174,000. 84.90% of the stock is owned by institutional investors.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply